APMD
Apnimed, Inc.
Set alert
16.40 USD -0.94 -5.42%
16.16 Day range 17.36
16.40 52-week range 32.55
- YTD
- -34.40%
- 1 year
- -34.40%
- Open
- 17.10
- Prev close
- 17.34
- Mkt cap
- 682.74M
- Vol
- 466.52K
- Avg vol
- 508.85K
- EPS
- 7.22
- P/E
- 2.27
- Div yield
- 0.00%
More statistics
- Low
- 16.16
- High
- 17.36
- Forward P/E
- -6.42
- Beta
- 0.00
- Short ratio
- 1.05
- Inst. own
- 18.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 27.74
- 200-d avg
- 27.74
- 1y target
- 50.33
Key statistics
- Market cap
- 1.06B
- Enterprise value
- 1.25B
- Trailing P/E
- 4.46
- Forward P/E
- -6.42
- PEG ratio
- 0.00
- Price / sales
- 9.23
- Price / book
- 0.00
- EPS (TTM)
- 5.72
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 142.10%
- Revenue (TTM)
- 115.12M
- Revenue growth
- -29.40%
- Free cash flow
- 0
- Total cash
- 172.80M
- Total debt
- 80.35M
- Return on equity
- 0.00%
- Shares outstanding
- 41.63M
- Short % of float
- 0.00%
- 50-day average
- 27.74
- 200-day average
- 27.74
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 50.33 +206.9% upside
Now 16.40
- Target (low)
- 41.00
- Target (mean)
- 50.33
- Target (high)
- 60.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.34.
Financials — quick view
APMD Revenue — quarterly 12.08M
APMD Net income — quarterly 125.94M
APMD EPS — quarterly 26.25
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 8, 2026 | Jun 30, 2026 | -0.48667 | 3.92 | +4.41 | +905.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 25, 2026 | LifeSci Capital | init | — | Outperform |
| Aug 25, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Aug 25, 2026 | Evercore ISI Group | init | — | Outperform |
| Aug 25, 2026 | B of A Securities | init | — | Buy |
About Apnimed, Inc.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- apnimed.com
News
- Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026
- Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Apnimed, Inc. (NASDAQ:APMD) Stock Short Interest Jumps 55.7%
- Apnimed, Inc. (NASDAQ:APMD) Given Consensus Rating of “Moderate Buy” by Brokerages
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Apnimed: What We Know Heading Into The Feb PDUFA
- Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M
- Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Apnimed, Inc.’s Quiet Period Will End on September 9th (NASDAQ:APMD)
Your note
Sign in to keep a note on APMD — it syncs with the Stock Master app.